Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor

Gynecologic Oncology

Volumn 62, Issue 1, 1996, Pages 67-72

  Tamakoshi, Koji ^a   Kikkawa, Fumitaka ^a   Shibata, Kiyosumi ^a   Tomoda, Kiyoshi ^a   Obata, Naoko H ^a   Wakahara, Fumiyo ^a   Tokuhashi, Yahito ^a   Ishikawa, Hisatake ^b   Kawai, Michiyasu ^c   Tomoda, Yutaka ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c NAGOYA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CHILD; DIAGNOSTIC VALUE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; TUMOR BIOPSY;

EID: 0030200820     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0191     Document Type: Article

References (22)

1. 1. Taylor, H. C. Malignant and semi-malignant tumors of the ovary, Surg. Gynecol. Obstet. 48, 701-712 (1929).
2. 2. International Federation of Gynecology and Obstetrics. Classification and strategy of malignant tumors in the female pelvis, Acta Obstet. Gynecol. Scand. 50, 1-7 (1971).
3. 3. Serov, S. F., Scully, R. E., and Sobin, L. H. International histologic typing of ovarian tumors, World Health Organization, Geneva (1973).
4. 4. Kliman, L., Rome, R. M., and Fortune, D. W. Low malignant potential tumors of the ovary: A study of 76 cases, Obstet. Gynecol. 68, 338-344 (1986).
5. 5. Casey, A. C., Bell, D. A., Lage, J. M., Fuller, A. F., Nikrui, N., and Rice, L. W. Epithelial ovarian tumors of borderline malignancy: Long-term follow up, Gynecol. Oncol. 50, 316-322 (1993).
6. 6. Chambers, J. T., Merino, M. J., Kohorn, E. I., and Schwartz, P. E. Borderline ovarian tumors, Am. J. Obstet. Gynecol. 159, 1088-1094 (1988).
7. 7. Rice, L. W., Berkowitz, R. S., Mark, S. D., Yavner, D. L., and Lage, J. M. Epithelial ovarian tumors of borderline malignancy, Gynecol. Oncol. 39, 195-198 (1990).
8. 8. International Federation of Gynecology and Obstetrics. Changes in definitions of clinical staging for carcinoma of the cervix and ovary, Am. J. Obstet. Gynecol. 156, 263-264 (1987).
9. 9. Julian, C. G., and Woodruff, J. D. The biologic behavior of low grade papillary serous carcinoma of the ovary, Obstet. Gynecol. 40, 860-867 (1972).
10. 10. Aure, J. C., Holg, K., and Kolstad, P. Clinical and histologic studies of ovarian carcinoma, Obstet. Gynecol. 37, 1-9 (1971).
11. 11. Hart, W. R., and Norris, H. J. Borderline and malignant mucinous tumors of the ovary: Histologic criteria and clinical behavior, Cancer 31, 1031-1045 (1973).
12. 12. Tazelaar, H. D., Bostwick, D. G., Ballon, S. C., Hendrickson, M. R., and Kempson, R. L. Conservative treatment of borderline ovarian tumors, Obstet. Gynecol. 66, 417-422 (1985).
13. 13. Bast, R. C., Feeney, M., Lazarus, H., Nadler, L. M., Clovin, R. B., and Knapp, R. C. Reactivity of a monoclonal antibody with human ovarian carcinoma, J. Clin. Invest. 68, 1331-1337 (1981).
14. 14. Bast, R. C., Klug, T. L., Jhon, E. S., Jenison, E., Niloff, J. M., Lazarus, H., Berkowitz, R. S., Leavitt, T., Griffiths, T., Parker, L., Zurawski, V. R., and Knapp, R. C. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer, N. Engl. J. Med. 309, 883-887 (1983).
15. 15. Einhorn, N., Bast, R. C., Knapp, R. C., Tjernberg, B, and Zurawski, V. R. Preoperative evaluation of serum CA125 levels in patients with primary epithelial ovarian cancer, Obstet. Gynecol. 67, 414-416 (1986).
16. 16. Brioschi, P. A., Irion, Bischof, P., Bader, M., Forni, M., and Krauer, F. Serum CA125 in epithelial ovarian cancer: A longitudinale study, Br. J. Obstet. Gynecol. 94, 196-201 (1987).
17. 17. Rice, L. W., Lage, J. M., Berkowitz, R. S., Goodman, A., Muto, M. G., Knapp, R. C., and Bell, D. A. Preoperative serum CA125 levels in borderline tumors if the ovary, Gynecol. Oncol. 46, 226-229 (1992).
18. 18. Canny, P. A., Wilkinson, P. M., James, R. D., and Moore, M. CA19-9 as a marker for ovarian cancer: Alone and in comparison with CA125, Br. J. Cancer 52, 131-133 (1985).
19. 19. Charpin, C., Bhan, A. D., Zurawski, V. R. Jr., and Scully, R. E. Carcinoembryonic antigen (CEA) and carbohydrate determinant 19-9 (CA19-9) localization in 121 primary and metastatic ovarian tumors: An immunohistochemical study with the use of monoclonal antibodies, Int. J. Gynecol. Pathol. 1, 231-245 (1982).
20. 20. Stall, K. E., and Martin, E. W. Plasma, carcinoembryonic antigen levels in ovarian cancer patients: A chart review and summary of published data, J. Reprod. Med. 26, 75 (1981).
21. 21. Teshima, H., Kitamura, H., Mizoguchi, Y., Hino, S., Mizutani, K., Mori, H., and Kigawa, T. Immunohistochemical and immunoelectron microscopic study of an amylase-producing, CA19-9 positive ovarian mucinous cystsdenocarcinoma, Gynecol. Oncol. 30, 372-380 (1988).
22. 22. Panza, N., Pacilio, G., Campanella, L., Peluso, G., Battista, C., Amoriello, A., Utech, W., Vacca, C., and Lombardi, G. Cancer antigen 125, tissue polypeptide antigen, carcinoembryonic antigen, and beta-chain human chorionic gonadotropin as serum markers of epithelial ovarian carcinoma, Cancer 61, 76-83 (1988).